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Background. Uric acid can acutely activate various inflammatory transcription factors. Since high levels of oxyradicals and lower
antioxidant levels in septic patients are believed to result in multiorgan failure, uric acid levels could be used as a marker of oxidative
stress and poor prognosis in patients with sepsis. Design. We conducted a prospective cohort study on Medical Intensive Care Unit
(MICU) patients and hypothesized that elevated uric acid in patients with sepsis is predictive of greater morbidity. The primary end
point was the correlation between hyperuricemia and the morbidity rate. Secondary end points were Acute Kidney Injury (AKI),
mortality, Acute Respiratory Distress Syndrome (ARDS), and duration of stay. Results. We enrolled 144 patients. 54 (37.5%) had the
primary end point of hyperuricemia. The overall morbidity rate was 85.2%. The probability of having hyperuricemia along with
AKI was 68.5% and without AKI was 31.5%. Meanwhile the probability of having a uric acid value <7 mg/dL along with AKI was
18.9% and without AKI was 81.1% (𝑝 value < 0.0001). Conclusion. We report that elevated uric acid levels on arrival to the MICU in
patients with sepsis are associated with poor prognosis. These patients are at an increased risk for AKI and ARDS.

1. Introduction
In humans uric acid is the final oxidative product of purine
metabolism through the action of xanthine oxidase or xanthine dehydrogenase. Approximately two-thirds of uric acid
is excreted by the kidney, and the rest is excreted by the
gastrointestinal tract. In addition some uric acid is degraded
in the body after reaction with oxidants or peroxynitrite
[1]. Uric acid occurs predominantly as a urate anion under
physiologic pH. In the kidney, urate is filtered readily by
the glomerulus and subsequently reabsorbed by the proximal
tubular cells of the kidney; normal fractional excretion of uric
acid is approximately 10% [2]. Normal levels of blood uric
acid are typically 3.4–7.2 mg/dL for men and 2.4–6.1 mg/dL
for women. Since the last century elevated uric acid levels
have been noted to be associated with atherosclerosis [3–7],
hypertension, hyperinsulinemia [8, 9], and chronic kidney
disease [10]. Uric acid has been shown to be elevated in
hypoxic states such as chronic heart failure [11, 12] and

obstructive pulmonary disease [13, 14]. Hyperuricemia is
defined as the accumulation of serum uric acid beyond
its solubility point in water and develops due to uric acid
overproduction, undersecretion, or both [15].
Uric acid can induce acute inflammation of the renal
epithelial cells via uric acid crystals. Uric acid can also have
an impact in the human body by its noncrystal effects. It
may cause endothelial dysfunction and cause an afferent renal
arteriolopathy and tubulointerstitial fibrosis in the kidney
by activating the renin-angiotensin-aldosterone system [16],
activate various inflammatory transcription factors [17], and
induce systemic cytokine production such as tumor necrosis
factor alpha [18] and local expression of chemokines such as
monocyte chemotactic protein 1 in the kidney and cyclooxygenase 2 (COX-2) in blood vessels [19]. Experimentally
induced hyperuricemia in rats leads to reduced urinary
nitrite levels and systemic and glomerular hypertension [20,
21]. Other in vitro experimental studies have shown that uric
acid decreases nitric oxide production [22] and also may lead
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to nitric oxide depletion [23]. The noncrystal effects of uric
acid remain contentious because, under physiologic concentrations, urate is a powerful antioxidant that can scavenge
superoxide, hydroxyl radicals, and singlet oxygen [24].
Sepsis is a serious medical condition characterized by
a whole-body inflammatory state (systemic inflammatory
response syndrome) and the presence of a known or suspected infection that has severe consequences [25]. Hence
majority of intensive care unit patients undergo ischemicreperfusion injury and inflammation to varying degrees
during their hospitalization. Uric acid may be a factor playing
a role in these processes since it has both oxidant and
antioxidant properties. Since high levels of oxyradicals and
lower antioxidant levels in patients with sepsis are believed
to result in multiorgan failure, the measurement of uric
acid levels could be possibly used as a marker of oxidative
stress in patients with sepsis. Hence we decided to conduct
a prospective cohort study in Medical Intensive Care Unit
(MICU) patients admitted with sepsis to see if there is any
significance of serum uric acid with respect to the morbidity
rate. We hypothesized that elevated uric acid levels at the early
hours of sepsis can predict an increased risk of morbidities as
a single test.

2. Materials and Methods
2.1. Study Design. We conducted a prospective cohort study
among patients admitted to the Medical Intensive Care Unit
(MICU) at Ruby Memorial Hospital, West Virginia University (Morgantown, West Virginia), between January 2014
and July 2014. Patients or their Medical Power of Attorneys
provided written informed consent and all the protocol was
approved by the West Virginia University Office of Research
Integrity and Compliance (West Virginia University Institutional Review Board). Funding for this study was provided
through the West Virginia Clinical and Translational Science
Institute Pilot Grants Program.
2.2. Enrollment Criteria. Inclusion criteria were age >18
years and admission to the MICU with a working diagnosis
of sepsis based on the Society of Critical Care Medicine,
Surviving Sepsis Campaign 2012 definition [26]. Exclusion
criteria were as follows: (1) pregnant females and (2) patients
from an outside facility that have already been in the MICU
for more than 24 hours.
2.3. Data Collection and Definitions. Patients being admitted
to the MICU were screened for sepsis. Sepsis was defined
based on the Society of Critical Care Medicine, Surviving
Sepsis Campaign 2012 definition [26]. Once the patient met
the inclusion criteria then blood samples were obtained for
uric acid, basic metabolic profile, complete blood count, lactic
acid, phosphorus, albumin, and arterial blood gas. Repeat
samples for arterial blood gas and basic metabolic profile were
obtained at 24 and 48 hours. Subsequently, the electronic
health records were reviewed to gather the remaining data
such as the patients’ age, sex, weight, race, body mass index,
vital signs, comorbidities, ventilation status, need for renal
replacement therapy, and hospital course over a 72-hour
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period. During the course of the study all patients continued
to receive standard of care for their illnesses by the MICU
team. For the purpose of our study we defined hyperuricemia
as a uric acid level ≥7 mg/dL in both males and females. We
defined Acute Kidney Injury (AKI) as an absolute ≥0.3 mg/dL
increase in serum creatinine over a 48-hour time period from
the baseline creatinine based on the Acute Kidney Injury
Network (AKIN) definition [27]. We used as the baseline
creatinine value the patients’ creatinine value at the time of
initial presentation to the MICU. We calculated the Acute
Physiology and Chronic Health Evaluation (APACHE) II
score based on Knaus et al. [28] definition to help assess the
severity of disease in the MICU patient population. Acute
Respiratory Distress Syndrome (ARDS) was defined per the
Berlin definition [29].
2.4. Clinical Outcomes. The primary end point was the
correlation between hyperuricemia in patients presenting
with sepsis and the morbidity rate. We hypothesized that
elevated uric acid in patients presenting to the MICU with
sepsis is predictive of a greater morbidity rate. Hyperuricemia
in general is defined as a serum urate level of >7 mg/dL
(420 uM) in men and >6 mg/dL (300 uM) in women. For
the purpose of our study we defined hyperuricemia as a uric
acid level ≥7 mg/dL in both males and females. Secondary
end points were Acute Kidney Injury (AKI), mortality, Acute
Respiratory Distress Syndrome (ARDS), and duration of
stay in MICU. AKI was defined as an absolute ≥0.3 mg/dL
increase in serum creatinine over a 48-hour time period
from the baseline creatinine based on the Acute Kidney
Injury Network (AKIN) definition. We used as the baseline
creatinine value the patients’ creatinine value at the time
of initial presentation to the MICU. Additional end points
included need for renal replacement therapy and the patients’
stability to be transferred to a lower level of care.
2.5. Statistical Analyses. Percentages of measures by uric acid
level were compared using Chi squared tests for association.
For APACHE II scores, linear regression was performed to
assess the linear association with uric acid. All analyses were
performed in SAS 9.4.

3. Results
3.1. Baseline Characteristics. We enrolled and collected samples from 144 patients. The median age was 60.5 years. The
most prevalent comorbidities were Diabetes, coronary artery
disease, and cerebrovascular accident. Overall there were
57.6% males and 42.4% females and 39.6% of the enrolled
patient population were ≥65 years of age. Our patient population was predominantly Caucasian (97.2%) (see Table 1). Also
to note was that 47.8% of the overall patient population had
a body mass index (BMI) ≥30 (see Table 1 and Figure 1). The
BMI distribution in the overall population is given in Figure 1.
3.2. Acute Kidney Injury and Acute Respiratory Distress
Syndrome. Amongst 144 patients, 54 (37.5%) had the primary
end point of hyperuricemia. Within this subset of patients
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Table 1: Baseline characteristics.

Characteristics
Age
<30 years old
30–65 years old
≥65 years old
Sex
Females
Males
Ethnicity
Caucasian
Black
BMI
18.5–24.9
25–29.9
≥30
Comorbidities
DM
CAD
Severe pulmonary disease
CHF
CVA
h/o malignancy
∗

Overall 𝑁 (%)

Uric acid
High 𝑁 (%)

Low 𝑁 (%)

10 (6.9%)
77 (53.5%)
57 (39.6%)

3 (5.6%)
30 (55.6%)
21 (38.9%)

7 (7.8%)
47 (52.2%)
36 (40.0%)

61 (42.4%)
83 (57.6%)

23 (42.6%)
31 (57.4%)

38 (42.2%)
52 (57.8%)

140 (97.2%)
3 (2.1%)

51 (94.4%)
2 (3.7%)

89 (98.9%)
1 (1.1%)

37 (27.2%)
34 (25.0%)
65 (47.8%)

12 (22.6%)
8 (15.1%)
33 (62.3%)

25 (30.1%)
26 (31.3%)
32 (38.6%)

53 (36.8%)
37 (25.7%)
23 (16.0%)
14 (9.7%)
24 (16.7%)
23 (16.0%)

22 (40.7%)
15 (27.8%)
7 (13.0%)
8 (14.8%)
7 (13.0%)
10 (18.5%)

31 (34.4%)
22 (24.4%)
16 (17.8%)
6 (6.7%)
17 (19.9%)
13 (14.4%)

𝑝 value∗
0.8519

0.9653

0.2436

0.0195

0.4482
0.6576
0.4452
0.1101
0.3556
0.5182

Chi square test.

27.20%

47.80%

25%

Normal weight 18.5–24.9
Overweight 25–29.9
Obese 30+

Figure 1: BMI distribution of the total patient population.

the overall morbidity rate was 85.2% of which AKI accounted
for 68.5% and 83.8% had ARDS. Of those with ARDS 70.6%
required mechanical ventilation. In terms of ARDS, although
a high percentage of patients incurred this in our sample population, the incidence was not statistically significant most
likely due to the small sample size of the study population.

The probability of having hyperuricemia along with AKI is
about 68.5% and without AKI is about 31.5%. Meanwhile the
probability of having a uric acid value <7 mg/dL along with
AKI is 18.9% and without AKI about 81.1%. These probabilities are statistically significant with a 𝑝 value of <0.0001. Of
the 37 patients who had hyperuricemia and AKI, only 3 (8.1%)
needed renal replacement therapy; meanwhile for the overall
sample 2.08% ended up having renal replacement therapy in
the first 48 hrs of their MICU hospitalization.
The most prevalent comorbidities among patients with
hyperuricemia were Diabetes Mellitus (40.7%), coronary
artery disease (27.8%), and history of a malignancy (18.5%).
Meanwhile the most prevalent comorbidities in patients with
hyperuricemia who incurred AKI were Diabetes (43.3%),
coronary artery disease (32.4%), and Congestive Heart Failure (21.6%) (see Figure 2).
3.3. Severity of Illness. Elevated lactic acid levels can be
used as a marker for indicating impaired tissue oxygenation,
leading to increased anaerobic metabolism and suggesting
the presence of hemodynamic instability resulting in lack of
appropriate organ perfusion. In our lab elevated lactic acid
level was considered as any level >2.2 mmol/L. Of the patients
with hyperuricemia 35.2% had an elevated lactic acid level.
Our data is suggestive of an association between high uric
acid levels and elevated lactic acid levels; however the results
are not statistically significant most likely due to the small
sample size.
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Figure 2: Comorbidities in patients with hyperuricemia and AKI.
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Figure 3: Uric acid levels and APACHE II score.

The Acute Physiology and Chronic Health Evaluation
(APACHE) II score helps predict the severity of disease and
the prognosis of the patients in the intensive care unit. For
the purpose of our study we defined an elevated APACHE II
score as any value ≥20 as scores of ≥20 have been associated
with a greater than 35% predictive mortality rate. Of the 144
study patients 40 patients were excluded while calculating
the APACHE II score as they did not have an arterial blood
gas result. In our study of the patients with hyperuricemia
83.3% had an APACHE II score ≥20 while only 16.7% had an
APACHE II score <20. The probability of having a uric acid
level <7 mg/dL with an APACHE II score of ≥20 was 54.4%
and with an APACHE II score of <20 was 45.6%. These probabilities are statistically significant with a 𝑝 value of 0.0034. In
addition a linear correlation between the APACHE II score
and uric acid value was noted, 𝑝 value of 0.014 (see Figure 3).
Hypoalbuminemia is a common problem associated
with patients with acute and chronic medical conditions.
The normal albumin values are 3.5–4.5 g/dL. We defined
hypoalbuminemia as levels ≤3.5 gm/dL. Based on this of the
patients with hyperuricemia 88.5% had hypoalbuminemia
while 91.7% of those with a uric acid level <7 mg/dL had a low
albumin level. The results were not statistically significant as
the 𝑝 value was 0.5367.

Hypophosphatemia has been hypothesized to be associated with early sepsis and the presence of elevated inflammatory cytokines. As per our results the overall incidence
of hypophosphatemia in our sample population was only
16.7% and in the subgroup with hyperuricemia 7.4% had
a serum phosphorus level of ≤2.5 mg/dL. Although of the
nonhyperuricemic patients 22.2% had a low phosphorus
level and these values are significantly different with 𝑝 value
of 0.0209, no correlation between hypophosphatemia and
elevated uric acid levels was noted in our study.
Duration of stay in the MICU helps indirectly identify the
degree of severity of illness of the ICU patients. We found that
overall 75% and 54.2% of our enrolled patients were still in the
MICU and not transferred to a lower level of care at 48 and 72
hours, respectively. The probability of having hyperuricemia
and still being in the MICU at 48 and 72 hours was 81.5% and
64.8%, respectively, while the probability of having a uric acid
level <7 mg/dL and being in the MICU at 48 and 72 hours was
71.1% and 47.8%, respectively. These probabilities are different
with a 𝑝 value of 0.1209 and 0.0464, respectively. For those
with AKI, there was no difference in still being in the MICU
by uric acid level, 82.4% versus 86.5% at 48 hours and 70.6%
versus 70.6% at 72 hours. While not significant, there was a
higher probability of still being in the MICU for those with
ARDS and high uric acid levels compared to those with ARDS
and low uric acid levels, 93.6% versus 81.5% (𝑝 value = 0.20)
at 48 hours and 77.4% versus 68.5% (𝑝 value = 0.38).

4. Discussion
In this prospective cohort study, we report that elevated uric
acid levels on arrival to the MICU in patients with sepsis are
associated with a poor prognosis; that is, an increased risk for
AKI, ARDS, marks an increased severity of illness measured
as per the APACHE II score and increased duration of stay
in the MICU. One may postulate that during sepsis there is
an increased level of antioxidant response to counterbalance
the excessive proinflammatory cytokines and oxidative stress,
and this altered level of antioxidant defense leads to immune
dysfunction and poor outcomes. In a systemic inflammatory
response, both endothelial cells and neutrophils are activated
to release oxygen-derived free radicals [30]. It seems that
these oxyradicals play a role in causing or propagating the
systemic inflammatory response syndrome (SIRS) in lifethreatening conditions and that the imbalance in redox state
reflects both oxidative stress and tissue damage [31, 32].
Serum uric acid, like other antioxidants such as albumin,
bilirubin, or vitamins A, C, and E, is a powerful free radical
scavenger and increases in response to acute oxidative stress
[33, 34]. Uric acid formation may even provide a significant
antioxidant defense mechanism against nitration by peroxynitrite in rat heart during hypoxia [35]. Hence uric acid is
believed to be an important marker of oxidative stress.
The mechanisms for increased uric acid in sepsis are
unknown and could be due to increased production as well
as decreased excretion. Severe sepsis and septic shock may
induce ischemia or hypoxia in multiple organs, which further
increases the change in xanthine/hypoxanthine to uric acid
through activation of xanthine oxidase in microvascular
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endothelium [36, 37]. When uric acid accumulates in blood
vessels and deposits on the endothelium of vessels, the release
of vasorelaxation factors is hampered [3], and vascular contraction interfered, leading to a series of pathophysiological
processes and dysfunction of internal organs especially the
kidney. Development of AKI during sepsis increases patient
morbidity, predicts higher mortality, has a significant effect
on multiple organ functions, is associated with an increased
length of stay in the intensive care unit, and hence consumes
considerable healthcare resources [25].
The first important finding of our study is that hyperuricemia is associated with AKI in patients with early sepsis.
The development of AKI has significant effect on prognosis.
For example, whereas the acute operative and postoperative
mortality rate after cardiovascular surgery varies between 1
and 2%, this increases to 10 to 38% if renal insufficiency
occurs and to >50% if dialysis is required [38, 39]. In general
the septic patient population is a very complex subset of
patients and majority of the time they have multiple organ
involvement and are very sick patients. They are at risk for
developing AKI due to changes in hemodynamics, exposure
to various medications, changes in the functional capacity of
other organs such as the heart and liver, and numerous other
factors. Uric acid may be one of the factors contributing to it
too.
Uric acid can cause AKI due to several mechanisms
ranging from direct tubular toxicity from crystal induced
injury to indirect injury secondary to the release of vasoactive
mediators and oxidative stress. Uric acid can cause AKI secondary to renal vasoconstriction which occurs in response to
the activation of the renin-angiotensin system, catecholamine
release, oxidative stress, release of proinflammatory markers,
and decreased nitric oxide levels. Renal vasoconstriction
occurs in rats with experimentally induced hyperuricemia
and is characterized by a marked increase in resistance of
the afferent (and, to a lesser extent, efferent) arterioles and
a reduction in single nephron GFR [40]. Uric acid strongly
inhibits nitric oxide release from endothelial cells [41]. Khosla
et al. [41] have demonstrated a reduction in plasma nitrites
(metabolites of NO) in hyperuricemic rats that can be rescued
by allopurinol. Uric acid levels have been shown by Zoccali
et al. [42] to correlate with endothelial dysfunction [42].
Uric acid stimulates an inflammatory response via increasing
various proinflammatory markers such as MCP and CRP.
Hyperuricemic rats have a significant increase in macrophage
infiltration in their kidneys independent of crystal deposition [20]. Despite having both oxidative and antioxidative
properties, it appears that in periods of significant degrees
of stress such as sepsis uric acids’ protective antioxidative
properties get overwhelmed and that despite increased levels
of oxidative stress leading to increased uric acid levels the
uric acid is more injurious than beneficial to the human body.
Hence uric acid may be an early marker of impending AKI
in patients with sepsis and could be used to predict the risk
for AKI in septic patients. This further raises the question of
whether the treatment of hyperuricemia in early sepsis could
potentially decrease the risk for AKI.
Increased uric acid levels play a role not only in the
occurrence of AKI but also in the progression of CKD. Uric
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acid levels are increased in subjects with renal disease as
the result of reduction in GFR and renal urate excretion.
Chonchol et al. have reported that uric acid levels are
associated strongly with prevalent CKD [43]. Because of
progressive loss of GFR, patients with CKD have decreased
renal clearance of uric acid and thus greater serum uric acid
levels than the general population [44].
The second important finding of our study is that hyperuricemia correlated with an elevated APACHE II score. This
coincides with Jabs et al. [45] findings as they too found
that plasma uric acid levels increased in relation to higher
APACHE II scores. Chuang et al. [46] also found that an
increase in serum uric acid had a positive correlation with
total antioxidant capacity and APACHE II scores in patients
with severe sepsis and septic shock. This suggests that uric
acid may be an important contributor to total antioxidant
capacity and that hyperuricemia may be an early predictive
marker of poorer clinical outcomes in patients with sepsis.
This raises the question then in the management of patients
with early sepsis if the hyperuricemia should be treated to
decrease the degree of injury that it may cause and decrease
the morbidity and mortality rate in this patient population.
Although it is known that uric acid has both oxidant and
antioxidant properties the overall impact on the human body
appears to be more injurious than protective. Hence perhaps
the MICU can use uric acid level as a single marker to predict
the severity of illness in critically ill patients presenting to the
MICU rather than the slew of tests and variables needed to
calculate the APACHE II score.
The third important finding of our study was that hyperuricemia noted in the septic population correlated with an
increased probability of having the patient still in the MICU
at 72 hours. This again suggests that uric acid may indeed be
considered as a marker of severity of illness like the APACHE
II score and can help predict that those with an elevated uric
acid level at initial presentation are more likely to be still
in the MICU at 72 hours versus those with a uric acid level
less than 7 mg/dL. Thus raising thoughts that will treatment
of hyperuricemia improve patient outcomes and decrease
length of stay in the MICU?
In our study we found that although there was a high
incidence of ARDS noted in this septic patient population,
there was no statistically significant association of hyperuricemia with ARDS. Thus although uric acid levels may
be used to predict severity of illness, length of stay in the
MICU, and risk for AKI, it cannot at least at this time help
us predict the incidence of ARDS. This could potentially be
due to the small patient population that we had for our study,
especially since increasing uric acid levels have been reported
by Nagaya et al. [47] to correlate with clinical severity of
primary pulmonary hypertension and has an independent
association with long-term mortality of patient with primary
pulmonary hypertension. Also from our study we found that
although a high percentage of our patient populations were
obese and a high percentage of those with hyperuricemia
were obese, the results were not statistically significant. This
was most likely due to the small sample size.
We acknowledge several limitations of this study, including modest sample size, enrollment of patients from
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the MICU and not the surgical intensive care unit, predominant Caucasian patient population, and short followup period. By virtue of the single-center study design, the
results may not be generalizable to other MICU settings. If
we had a larger sample size, perhaps the linear correlation
between hyperuricemia with ARDS, obesity, and lactic acid
levels may have become more apparent. Given the fact that
the study center was located in West Virginia which is ranked
as number two in terms of the state with the highest obesity
rate in the USA, there could be potentially some degree of
effect on our study results as hyperuricemia has been believed
to often precede the development of obesity. So the possibility
that our patient population already had an elevated uric acid
level prior to being septic may be a factor increasing their
risk of overall morbidity and degree of illness severity. Hence
possibly we should test and potentially treat the general
population for hyperuricemia to improve patient outcomes,
which is a thought. Also to note is that our patient population
was predominantly Caucasian, so the generalizability of the
results is limited. The other limitations include that we did
not have the baseline creatinine on the patients from prior to
admission and hence did not know for certain what percentage of the patients had CKD prior to presentation. This is an
important factor as patients with CKD are often noted to have
an elevated uric acid level and it is debatable that elevated
uric acid levels are injurious to the renal parenchyma as well
as that CKD has been associated with decreased uric acid
excretion and subsequently results in elevated uric acid levels.
Thus, in order to minimize the degree of potential errors we
used the patients’ admission creatinine as the baseline value
to mark the occurrence of AKI. Other potential limitations
include the fact that we only followed the patients for 72 hours
and that we did not trend the uric acid level during the course
of the hospital stay to see if there was a potential change which
was reflective of the patients hospital course. Throughout the
analysis of the data we considered all the above-mentioned
limitations especially the sample size and selection bias as it
may have influenced our study results to a certain degree.
Subsequently our study sets the stage for further randomized
control trials that are multicenter and encompass a greater
sample size and population diversity to help better elucidate
and confirm our findings.

5. Conclusion
Our study findings simply demonstrate that hyperuricemia
may be associated with poorer clinical outcomes in patients
admitted to the MICU with sepsis. Serum uric acid levels may
be potentially used as a sole marker of severity of illness as
well as a predictor of morbidity in patients presenting to the
MICU with sepsis. Further studies are needed to confirm our
observations and elucidate the underlying mechanisms for
hyperuricemia in sepsis.
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